---
title: "LFCR: Revenue and profit declined, with liquidity sufficient but major preferred stock redemptions looming"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294961714.md"
description: "Revenue and gross profit declined year-over-year due to lower CDMO sales and higher interest expense, resulting in a larger net loss. Liquidity remains adequate, but upcoming preferred stock redemptions require new financing or strategic actions.Original document: Lifecore Biomedical, Inc. [LFCR] SEC 10-Q Quarterly Report — Aug. 5 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-05T11:48:55.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294961714.md)
  - [en](https://longbridge.com/en/news/294961714.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294961714.md)
---

# LFCR: Revenue and profit declined, with liquidity sufficient but major preferred stock redemptions looming

Revenue and gross profit declined year-over-year due to lower CDMO sales and higher interest expense, resulting in a larger net loss. Liquidity remains adequate, but upcoming preferred stock redemptions require new financing or strategic actions.

Original document: Lifecore Biomedical, Inc. \[LFCR\] SEC 10-Q Quarterly Report — Aug. 5 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [LFCR.US](https://longbridge.com/en/quote/LFCR.US.md)

## Related News & Research

- [LFCR: Q2 revenue fell 6.2% to $34.2M, but new business wins and guidance reaffirmed](https://longbridge.com/en/news/294961069.md)
- [Lifecore Biomedical faces $52.1M Series A preferred redemption due Dec. 28, 2026](https://longbridge.com/en/news/291592245.md)
- [GLAND: Q1 FY 2027 delivered robust growth, with 20% higher revenue and strong CDMO momentum](https://longbridge.com/en/news/295428719.md)
- [SAILIFE: Q1FY27 revenue rose 12% year-over-year, driven by strong CRO and CDMO growth and higher margins](https://longbridge.com/en/news/295202930.md)
- [BioHarvest Reports Second Quarter 2026 Financial Results and Provides Business Update | BHST Stock News](https://longbridge.com/en/news/295522189.md)